Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials

Autor:	Myat Min Han, Thura Win Htut, Kyaw Zin Thein
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Chronic lymphocytic leukemia Immunology medicine.disease law.invention Randomized controlled trial law Meta-analysis Internal medicine medicine Immunology and Allergy Acalabrutinib In patient business
Zdroj:	Journal of Immunotherapy and Precision Oncology. 5:43-47
ISSN:	2590-017X 2666-2345
Popis:	Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinical trials to determine the risks of acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukemia. Patients on acalabrutinib experienced higher risk of any-grade cardiac events (risk ratio, 1.75; p = 0.01) while there was a considerable trend toward statistical significance in the risk of any-grade atrial fibrillation (risk ratio, 2.56; p = 0.05). There was no significant increase in the risk of hypertension or high-grade cardiac events or atrial fibrillation in the acalabrutinib group.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d0e2c99232c74e0c67079c060e14a8c https://doi.org/10.36401/jipo-21-12 Zobrazit plný text záznamu